Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438904 | 0.90 | MAOB (0.63) | MAOBMAOAGRM5CYP1A2NR4A2 | |
| SCHEMBL4425403 | 0.81 | MAOB (0.67) | MAOBMAOAGRM5CYP1A2NR4A2 | |
| SCHEMBL20905162 | 0.76 | MAOB (0.58) | MAOBMAOAGRM5NR4A2 | |
| SCHEMBL31419919 | 0.76 | MAOB (0.74) | MAOBMAOAGRM5NR4A2 | |
| SCHEMBL31419916 | 0.76 | MAOB (0.74) | MAOBMAOAGRM5NR4A2 | |
| SCHEMBL6439886 | 0.75 | MAOB (0.61) | MAOBMAOAGRM5CYP1A2 | |
| SCHEMBL861068 | 0.75 | MAOB (0.47) | MAOBMAOAGRM5CYP1A2NR4A2 | |
| SCHEMBL861069 | 0.75 | MAOB (0.47) | MAOBMAOAGRM5CYP1A2NR4A2 | |
| SCHEMBL2598011 | 0.75 | MAOB (0.47) | MAOBMAOAGRM5CYP1A2NR4A2 | |
| SCHEMBL2598012 | 0.75 | MAOB (0.47) | MAOBMAOAGRM5CYP1A2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539694-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6846832-B2 | 2,3-dihydro-isoindol-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014856-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885GRM5 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.